Exhibit 99.1 Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results 14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wisconsin, August 14, 2024 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary • Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 mi ...

Core Insights - Accuray Incorporated and Halifax Health have introduced the Radixact® System with VitalHold™ technology, marking the first use of this advanced patient positioning system for cancer treatment in the U.S. [1][5] - The VitalHold feature enhances precision in radiation delivery by providing effective patient positioning and monitoring throughout treatment [1][3][4] - The Radixact System is designed to accommodate a growing number of cancer cases, with an estimated 35% increase in new cancer cases in the U.S. projected between 2022 and 2040 [3] Company Overview - Accuray is focused on expanding the capabilities of radiation therapy to improve patient outcomes, emphasizing continuous innovation in oncology and neuro-radiosurgery [8] - Halifax Health is recognized for its comprehensive healthcare services, including a cancer treatment center that utilizes advanced technologies like the Radixact System [7] Technology and Features - The Radixact System is augmented with Accuray's ClearRT® helical CT imaging and Synchrony® real-time adaptive delivery technologies, facilitating faster and safer treatment for various cancer types [2] - VitalHold incorporates a surface-guided radiotherapy (SGRT) solution, allowing for tattoo-free positioning and enhancing patient comfort while ensuring accurate treatment delivery [4][5] - The system supports deep inspiration breath hold (DIBH) treatments, which help minimize radiation exposure to surrounding organs, thereby reducing potential complications [4]

MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024.The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. Th ...

When it comes to investing in top penny stocks, a word of caution.Always do your due diligence before buying. Make sure it has volume. Know upfront that you can lose a lot of money. And don’t get caught up in the promotional promises of turning $10,000 into millions without first doing your homework. As I’ll repeat below, penny stocks are frequently the playground for scam artists and market manipulators.Sure, some penny stocks turned out to be massive success stories, like Apple (NASDAQ:AAPL), Ford (NYSE:F ...

The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speedHeidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing researchMADISON, Wis., June 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company's Radixact® System, equipped with its prop ...

Company Developments - Accuray Incorporated (ARAY) has entered into an agreement with TrueNorth Medical Physics LLC to enhance the capabilities of radiation oncology departments, providing supplementary services to hospitals [1][2] - TrueNorth will support the commissioning, physics, and dosimetry of Accuray's TomoTherapy, Radixact, and CyberKnife platforms, offering customized services tailored to hospital needs [2] - Accuray has been actively forming partnerships, including a collaboration with Oncopole Claudius Regaud and Airbus SAS to develop an AI-driven solution for predicting radiotherapy system performance [3] Industry Prospects - The global radiation therapy market, valued at $7.3 billion in 2022, is projected to grow at a rate of 8%, reaching over $14.9 billion by 2032, driven by increased efficiency and market demand [4] Notable Developments - In June, Accuray received approval from the Chinese National Medical Products Administration for its Precision Treatment Planning System, enhancing treatment accuracy and expanding access to care for cancer patients in China [5] - New data presented at the 2024 Radiosurgery Society Meeting supports the use of the CyberKnife System for treating high-risk and recurrent prostate cancer [5] Price Performance - Over the past six months, ARAY's shares have decreased by 34.5%, contrasting with a 5.8% increase in the industry and a 15.2% rise in the S&P 500 [6]

MADISON, Wis., June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities. Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid – to help ensure they ha ...

Accuray Incorporated (ARAY) recently announced that the Chinese National Medical Products Administration (NMPA) approved the registration dossier of the Accuray Precision Treatment Planning System (TPS).The CNNC-Accuray joint venture Tomo C radiation therapy system and the Accuray Precision TPS are now compatible. These are likely to provide medical teams with a new way to administer highly accurate and precise radiation treatments, as well as expand access to care for more cancer patients in China.More on ...

MADISON, Wis., June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiothe ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:3D Systems Corporation (DDD) is 3D printing solutions company. The Zacks Consensus Estimate for its current year earnings has been revised 11.1% downward over the last 60 days.Accuray Incorporated (ARAY) is a radiation oncology company. The Zacks Consensus Estimate for its current year earnings has been revised 128.6% downward over the last 60 days.Brenntag SE (BNTGY) is a chemical distribution company.The Zacks Consensus Estimate for ...